No Other Permitted Uses Sample Clauses

No Other Permitted Uses. Except as otherwise set forth in this Agreement, You agree not to rent, lease, lend, upload to or host on any website or server, sell, redistribute, or sublicense the Apple Software, Apple Certificates, or any Services, in whole or in part, or to enable others to do so. You may not use the Apple Software, Apple Certificates, or any Services provided hereunder for any purpose not expressly permitted by this Agreement, including any applicable Attachments and Schedules. You agree not to install, use or run the Apple SDKs on any non-Apple-branded computer, and not to install, use or run iOS, watchOS, tvOS, iPadOS, macOS and Provisioning Profiles on or in connection with devices other than Apple-branded products, or to enable others to do so. You may not and You agree not to, or to enable others to, copy (except as expressly permitted under this Agreement), decompile, reverse engineer, disassemble, attempt to derive the source code of, modify, decrypt, or create derivative works of the Apple Software, Apple Certificates or any Services provided by the Apple Software or otherwise provided hereunder, or any part thereof (except as and only to the extent any foregoing restriction is prohibited by applicable law or to the extent as may be permitted by licensing terms governing use of open-sourced components or sample code included with the Apple Software). You agree not to exploit any Apple Software, Apple Certificates, or Services provided hereunder in any unauthorized way whatsoever, including but not limited to, by trespass or burdening network capacity, or by harvesting or misusing data provided by such Apple Software, Apple Certificates, or Services. Any attempt to do so is a violation of the rights of Apple and its licensors of the Apple Software or Services. If You breach any of the foregoing restrictions, You may be subject to prosecution and damages. All licenses not expressly granted in this Agreement are reserved and no other licenses, immunity or rights, express or implied are granted by Apple, by implication, estoppel, or otherwise. This Agreement does not grant You any rights to use any trademarks, logos or service marks belonging to Apple, including but not limited to the iPhone or iPod word marks. If You make reference to any Apple products or technology or use Apple’s trademarks, You agree to comply with the published guidelines at xxxxx://xxx.xxxxx.xxx/legal/intellectual- property/guidelinesfor3rdparties.html, as they may be modified by Apple fro...
Sample 1Sample 2Sample 3See All (48)
AutoNDA by SimpleDocs
No Other Permitted Uses. Institution agrees not to exploit the Service in any unauthorized way whatsoever, including, but not limited to, by trespass, burdening network capacity, or uploading malicious code. Any attempt to do so is a violation of the rights of Apple and its licensors. Institution may not license, sell, share, rent, lease, assign, distribute, host, permit timesharing or service bureau use, or otherwise make the Service (or any components thereof) available to any third-party, except as expressly permitted in this Agreement. Institution agrees that it will not use the Service to stalk, harass, mislead, abuse, threaten or harm or pretend to be anyone other than the entity that has enrolled, and Apple reserves the right to reject or block any accounts that could be deemed to be an impersonation or misrepresentation of another entity or person’s name or identity. Institution will not interfere with the Service, or with any security, digital signing, digital rights management, verification or authentication mechanisms implemented in or by the Service or by the Apple Software or any other related Apple software or technology, or enable others to do so. If Institution is a covered entity, business associate, representative of a covered entity or business associate (as those terms are defined at 45 C.F.R § 160.103), or otherwise a health care provider or entity, Institution agrees that it will not use any component, function or other facility of the Service to create, receive, maintain or transmit any “protected health information” (as such term is defined at 45 C.F.R § 160.103) or equivalent health data under applicable law, or use the Service in any manner that would make Apple a business associate of Institution or any third-party or otherwise directly subject Apple to applicable health privacy laws. All rights not expressly granted in this Agreement are reserved and no other licenses, immunity or rights, express or implied are granted by Apple, by implication, estoppel, or otherwise.
Sample 1Sample 2Sample 3See All (8)
No Other Permitted Uses. Except as otherwise set forth in this Agreement, You may not rent, lease, lend, upload to or host on any website or server, sell, redistribute, or sublicense the AT&T Development Tool Set or any services, in whole or in part, or to enable others to do so. You may not use the AT&T Development Tool Set or any services provided hereunder for any purpose not expressly permitted by this Agreement. You may not and You agree not to, or to enable others to, copy (except as expressly permitted under this Agreement), decompile, reverse engineer, disassemble, attempt to derive the source code of, modify, decrypt, or create derivative works of the AT&T Development Tool Set or any services provided by the AT&T Development Tool Set or otherwise provided hereunder, or any part thereof (except as and only to the extent any foregoing restriction is prohibited by applicable law or to the extent as may be permitted by licensing terms governing use of open-sourced components or sample code included with the AT&T Development Tool Set). You agree not to exploit any services provided hereunder in any unauthorized way whatsoever, including but not limited to, by trespass or burdening network capacity of the AT&T Service. If You breach any of the foregoing restrictions, You may be subject to prosecution and damages. All licenses not expressly granted in this Agreement are reserved and no other licenses, immunity or rights, express or implied are granted by AT&T, by implication, estoppel, or otherwise.
Sample 1Sample 2Sample 3
No Other Permitted Uses. Licensee agrees to use the Licensed Specifications, Source Code, and all other Licensed Technology solely to permit Proposed Products and Licensed Products to control, interface, communicate, or otherwise interoperate with Compatible Products in accordance with this Use License. Except as explicitly provided in this Use License, Licensee may not add to, delete from, extend, enhance, improve, modify or create any derivative works of any Licensed Technology, or modify any of the design, mechanical, electrical, or signal characteristics of any Licensed Technology, or use any Licensed Technology for any purpose not expressly permitted by this Use License. Licensee may not decompile, disassemble, or otherwise reverse engineer any software or hardware supplied or specified by Apple without Apple's express prior written consent, except to the extent permitted by applicable law that cannot be waived by this section. Nothing in this Use License shall be construed as an agreement to bring or prosecute actions against any third party that is infringing, misappropriating or violating any Licensed Technology. All rights not expressly granted in this Use License are reserved and no other licenses, immunity or rights, express or implied are granted, by implication, estoppel, or otherwise.
Sample 1Sample 2Sample 3
No Other Permitted Uses. You agree not to exploit the Program in any unauthorized way whatsoever, including, but not limited to, by trespass or burdening network capacity. Any attempt to do so is a violation of the rights of Apple and its licensors. All rights not expressly granted in this Agreement are reserved and no other licenses, immunity or rights, express or implied are granted by Apple, by implication, estoppel, or otherwise.
Sample 1Sample 2Sample 3
No Other Permitted Uses. Except as otherwise set forth in this Agreement, You may not use the SDK or any part of it for any purpose not expressly permitted by this Agreement. You may not reverse engineer, decompile or reverse compile the APIs or the Player firmware.
Sample 1
No Other Permitted Uses. Any use of SciFinder not specifically permitted under this Agreement, including but not limited to the use of federated search tools with SciFinder, distribution by assignment, sale, sublicense rather than Participating Members, loan or other means of transfer to any third party, and any commercial use, whether paid or unpaid, is strictly prohibited. LICENSEE’s right to use SciFinder is completely stated here and LICENSEE has no other, or any additional, rights to use it. CAS reserves and keeps all other rights in and to SciFinder and CAS data.
Sample 1
AutoNDA by SimpleDocs
No Other Permitted Uses. Licensee agrees to use the Licensed Specifications and Source Code (as described in Schedule B), and all other Licensed Technology, regardless of the source or manner through which Licensee obtains such materials, only to permit Proposed Products and Licensed Products to control, interface, communicate, or otherwise interoperate with Compatible OS Products in accordance with rights granted under this Use License, and not for any other purpose or in connection with any other products. Except as explicitly provided in this Use License, Licensee may not add to, delete from, extend, enhance, improve, modify or create any derivative works of any Licensed Technology, or modify any of the design, mechanical, electrical, or signal characteristics of any Licensed Technology, or use any Licensed Technology for any purpose not expressly permitted by this Use License. Licensee may not decompile, disassemble, or otherwise reverse engineer any software or hardware supplied or specified by Apple without Apple’s express prior written consent (except to the extent permitted by applicable law which cannot be waived by this subsection). Nothing in this Use License shall be construed as an agreement to bring or prosecute actions against any third party that is infringing, misappropriating or violating any Licensed Technology. All licenses not expressly granted in this Use License are reserved and no other licenses, immunity or rights, express or implied are granted, by implication, estoppel, or otherwise. Licensee agrees that it must not charge any fee for an end-user to access or use Licensed Technology in a Licensed Product after the point of sale, nor will Licensee permit any third-party distributor, re-seller or system integrator to impose any such fees on the end-user.
Sample 1
No Other Permitted Uses iSucceed shall have no right to reproduce or distribute the Courses.
Sample 1

Related to No Other Permitted Uses

  • Permitted Uses BA shall use Protected Information only for the purpose of performing BA’s obligations under the Contract and as permitted or required under the Contract and Addendum, or as required by law. Further, BA shall not use Protected Information in any manner that would constitute a violation of the Privacy Rule or the HITECH Act if so used by CE. However, BA may use Protected Information as necessary (i) for the proper management and administration of BA;

  • Permitted Use (a) Tenant shall, at all times during the Term, and at any other time that Tenant shall be in possession of any Property, continuously use and operate, or cause to be used and operated, such Property as a skilled nursing/ intermediate care/independent living/assisted living/ special care/group home facility as currently operated, and any uses incidental thereto. Tenant shall not use (and shall not permit any Person to use) any Property, or any portion thereof, for any other use without the prior written consent of Landlord, which approval shall not be unreasonably withheld, delayed or conditioned. No use shall be made or permitted to be made of any Property and no acts shall be done thereon which will cause the cancellation of any insurance policy covering such Property or any part thereof (unless another adequate policy is available) or which would constitute a default under any ground lease affecting such Property, nor shall Tenant sell or otherwise provide to residents or patients therein, or permit to be kept, used or sold in or about any Property any article which may be prohibited by law or by the standard form of fire insurance policies, or any other insurance policies required to be carried hereunder, or fire underwriter’s regulations. Tenant shall, at its sole cost (except as expressly provided in Section 5.1.2(b)), comply or cause to be complied with all Insurance Requirements. Tenant shall not take or omit to take, or permit to be taken or omitted to be taken, any action, the taking or omission of which materially impairs the value or the usefulness of any Property or any part thereof for its Permitted Use. (b) In the event that, in the reasonable determination of Tenant, it shall no longer be economically practical to operate any Property as currently operated, Tenant shall give Landlord Notice thereof, which Notice shall set forth in reasonable detail the reasons therefor. Thereafter, Landlord and Tenant shall negotiate in good faith to agree on an alternative use for such Property, appropriate adjustments to the Additional Rent and other related matters; provided, however, in no event shall the Minimum Rent be reduced or abated as a result thereof. If Landlord and Tenant fail to agree on an alternative use for such Property within sixty (60) days after commencing negotiations as aforesaid, Tenant may market such Property for sale to a third party. If Tenant receives a bona fide offer (an “Offer”) to purchase such Property from a Person having the financial capacity to implement the terms of such Offer, Tenant shall give Landlord Notice thereof, which Notice shall include a copy of the Offer executed by such third party. In the event that Landlord shall fail to accept or reject such Offer within thirty (30) days after receipt of such Notice, such Offer shall be deemed to be rejected by Landlord. If Landlord shall sell the Property pursuant to such Offer, then, effective as of the date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the net proceeds of sale received by Landlord multiplied by the Interest Rate. If Landlord shall reject (or be deemed to have rejected) such Offer, then, effective as of the proposed date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the projected net proceeds determined by reference to such Offer multiplied by the Interest Rate.

  • Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Botulinum Toxin Type A (Dysport®) ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Botulinum Toxin Type A (Botox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Botulinum Toxin Type A and B (Botox®) NHSE Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Botulinum Toxin Type A and B (Botox®) NHSE Focal spasticity in children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Brentuximab vedotin (Adcetris®) NHSE CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 RED Brentuximab vedotin (Adcetris®) NHSE Treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 RED Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 RED Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 RED Brexucabtage ne autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 RED Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 RED Brigatinib Alunbrig® NHSE ALK-positive advanced non-small- cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 RED Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Brimonidine tartrate gel (Mirvaso®) ICB Treatment of facial erythema (rosacea) Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Brincidofovir ((CMX001)) NHSE CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Brivaracetam Briviact ICB epilepsy as alternative to levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Brodalumab (Kyntheum®) ICB Moderate to severe plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA511 - Mar 18 RED Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA672 – February 2021 BLUE Brolucizumab Beovu® ICB diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA820 – August 2022 BLACK Bromocriptine () ICB Pharmacological neuroprotective therapy in Xxxxxxxxx'x disease (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 BLACK Bromocriptine mesilate (Parlodel®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk® ) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk® ) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Budesonide (oral viscous slurry) Pulmicort respules ICB eosinophilic oesophagitis in adults and paediatrics Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 RED Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA708 – June 2021 RED Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLUE Buprenorphine Long-Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 BLACK Bupropion (Zyban®) ICB ADHD and other mental health conditions Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Burosumab Crysvita®) NHSE X-linked hypophosphataemia in adults Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA993 – August 2024 RED Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 updated Sept 2024 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 RED Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Butyrophenon es (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in Xxxxxxxxx'x disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 RED C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cabazitaxel (Jevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 RED Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in Xxxxxxxxx'x disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 RED Cabotegravir Vocabria® NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 RED Cabozantinib (Cometriq®) NHSE For treating medullary thyroid cancer - as per NICE TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Cabozantinib (Cabometyx ®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 RED Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care TA928 – November 20 RED Cabozantinib Cabometyx® NHSE with nivolumab for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA964 – April 2024 RED Cabozantinib ▼ (Cabometyx ® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy - as per NICE TA 463 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA463 - Aug 17 RED Calcifidiol NHSE Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Double Red Calcium channel blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Canagliflozin ▼ (Invokana® ▼) ICB In combination therapy for treating type 2 diabetes - as per NICE TA 315 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA315 - Jun 14 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB As a 4th monotherapy option for treating type 2 diabetes - as per NICE TA 390 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA390 - May 16 BLACK Canakinumab (Ilaris®) ICB Treatment of gouty arthritis attacks and reducing the frequency of subsequent attacks - as per NICE TA 281 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA281 - Apr 13 BLACK Canakinumab (Ilaris®) NHSE Treatment of systemic juvenile idiopathic arthritis - - as per NHS England policy (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA302 - Nov 13 BLACK Cangrelor ▼ (Kengrexal® ▼) ICB Treatment for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti platelet therapy - as per NICE TA 351 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA351 - Jul 15 RED Cannabidiol Epidyolex® NHSE seizures caused by tuberous sclerosis complex Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA873 – March 2023 RED Cannabidiol with clobazam (Epidyolex®) NHSE Seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA614 - Dec 19

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!